While statins can prevent disease in older adults, they can also cause potentially serious side effects that could outweigh the benefits, according to a study published in the Annals of Internal Medicine.
While statins can prevent disease in older adults, they can also cause potentially serious side effects, according to a study published in the Annals of Internal Medicine.
The researchers used a computer simulation model to determine whether statins can be routinely administered to prevent heart disease in adults age 75 years or older. They found that while there were far fewer heart attacks, there were potential side effects such as muscle pain and weakness or mild declines in cognitive function.
“There’s been a lot of uncertainty over the use of statins in older adults,” senior author Kirsten Bibbins-Domingo, PhD, MD, a professor of medicine, epidemiology and biostatistics at the University of California, San Francisco (UCSF), said in a statement. “Prior studies have favored statin use because of the clear benefits to the heart and because serious side effects are rare. Unfortunately, we don’t have enough studies in older adults, and as a result don’t know enough about how common or how severe the side effects are.”
Treating adults between the ages of 75 and 94 years would prevent more than 100,000 myocardial infarctions and 68,000 deaths from coronary heart disease. There are 19 million Americans in this age group, and they are projected to account for 2.5 million myocardial infarctions and 3.1 million coronary heart disease deaths over the next decade, according to UCSF.
In addition, 30% of adults ages 75 to 94 were diagnosed with cardiovascular disease, which statins are widely used to combat. Because statins are relatively inexpensive, treating all older adults without heart disease would still be cost effective, according to the authors. However, the simulation projected a 10%-30% increased risk of cognitive impairments or function limitations.
“At effectiveness similar to that in trials, statins are projected to be cost-effective for primary prevention; however, even a small increase in geriatric-specific adverse effects could offset the cardiovascular benefit,” the authors concluded.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More